Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025Neuro-Oncology Practice

Preserved IDH mutation and methylation class in vorasidenib non-responders: a report of two cases

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMehdi TouatJLJacqueline Lehmann‐CheSKSalah Eddine Oussama Kacimi

Discussion

Loading...

Member takes

Overview

Case report shows vorasidenib failed to prevent tumor progression in non-responders with IDH mutation, indicating treatment challenges.

Key Points

  • Vorasi denib failed to prevent progression in non-responders with IDH-mutated glioma, showing complexities of treatment.
  • Molecular analysis confirmed persistence of the idh mutation and methylation class despite treatment failure, emphasizing resistance mechanisms.
  • Postoperative treatment included conventional therapies like chemotherapy and radiation, demonstrating alternative approaches after vorasidenib.
  • Findings suggest vorasidenib does not induce an idh-wild type clone that may lessen sensitivity to standard treatments.

Cite This Study

Touat et al. (2025) studied this question.

synapsesocial.com/papers/68c23595b210217d6477184ehttps://doi.org/10.1093/nop/npaf081
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P12.23.B IDH INHIBITION AT RELAPSE?2025
  2. 2P12.22.A A GENETIC MOUSE MODEL OF IDH-MUTANT GLIOMA RESPONDS TO MUTANT IDH INHIBITION AND REVEALS ENHANCED EFFICACY OF SALVAGE CHEMORADIATION AFTER VORASIDENIB2025
  3. 3JS05.7.A EARLY SEIZURE CONTROL WITH [18F]-DOPA PET RESPONSE AFTER IDH INHIBITION WITH VORASIDENIB.2025
  4. 4P17.06.A VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)2025 · 1 citations
  5. 5Early seizure freedom with [<scp><sup>18</sup>F</scp>]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report2025 · 4 citations